Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378901802> ?p ?o ?g. }
- W4378901802 endingPage "100683" @default.
- W4378901802 startingPage "100683" @default.
- W4378901802 abstract "Rationale and ObjectiveRavulizumab and eculizumab have shown efficacy for the treatment of atypical hemolytic uremic syndrome (aHUS), but real-world evidence for ravulizumab is limited owing to its more recent approval. This real-world database study examined outcomes for adult patients switching to ravulizumab from eculizumab and patients treated with individual treatments.Study DesignA retrospective, observational study using the Clarivate Real World Database.Setting and PopulationUS health-insurance billing data (January 2012 to March 2021) of patients aged 18 years or older with ≥1 diagnosis relevant to aHUS, ≥1 claim for treatment with eculizumab or ravulizumab, and no evidence of other indicated conditions.ExposuresTreatment-switch (to ravulizumab after eculizumab), ravulizumab-only, and eculizumab-only cohorts were examined.OutcomesClinical procedures, facility visits, health care costs, and clinical manifestations.Analytical ApproachPaired-sample statistical testing compared the mean numbers of claims for each group 0-3 months before (preindex period) and 0-3 months and 3-6 months after (postindex period) the index date (point of initiation with a single treatment or treatment switch).ResultsIn total, 322 patients met the eligibility criteria at 3-6 months postindex in the treatment-switch (n=65), ravulizumab-only (n=9), and eculizumab-only (n=248) cohorts. The proportions of patients with claims for key clinical procedures continued to be small after treatment switch and were small (0%-11%) across all cohorts at 3-6 months postindex. Inpatient visits were reduced in the postindex period across all cohorts. At 3-6 months after treatment switch, patients reported fewer claims for outpatient, private practice, and home visits and lower median health care costs. The proportions of patients with claims for clinical manifestations of aHUS were generally reduced in the postindex period compared with those of the preindex period.LimitationsLow patient numbers receiving ravulizumab only.ConclusionsThe health-insurance claims data showed a reduced health care burden for US adult patients after treatment with ravulizumab or eculizumab for treatment of aHUS. Ravulizumab and eculizumab have shown efficacy for the treatment of atypical hemolytic uremic syndrome (aHUS), but real-world evidence for ravulizumab is limited owing to its more recent approval. This real-world database study examined outcomes for adult patients switching to ravulizumab from eculizumab and patients treated with individual treatments. A retrospective, observational study using the Clarivate Real World Database. US health-insurance billing data (January 2012 to March 2021) of patients aged 18 years or older with ≥1 diagnosis relevant to aHUS, ≥1 claim for treatment with eculizumab or ravulizumab, and no evidence of other indicated conditions. Treatment-switch (to ravulizumab after eculizumab), ravulizumab-only, and eculizumab-only cohorts were examined. Clinical procedures, facility visits, health care costs, and clinical manifestations. Paired-sample statistical testing compared the mean numbers of claims for each group 0-3 months before (preindex period) and 0-3 months and 3-6 months after (postindex period) the index date (point of initiation with a single treatment or treatment switch). In total, 322 patients met the eligibility criteria at 3-6 months postindex in the treatment-switch (n=65), ravulizumab-only (n=9), and eculizumab-only (n=248) cohorts. The proportions of patients with claims for key clinical procedures continued to be small after treatment switch and were small (0%-11%) across all cohorts at 3-6 months postindex. Inpatient visits were reduced in the postindex period across all cohorts. At 3-6 months after treatment switch, patients reported fewer claims for outpatient, private practice, and home visits and lower median health care costs. The proportions of patients with claims for clinical manifestations of aHUS were generally reduced in the postindex period compared with those of the preindex period. Low patient numbers receiving ravulizumab only. The health-insurance claims data showed a reduced health care burden for US adult patients after treatment with ravulizumab or eculizumab for treatment of aHUS." @default.
- W4378901802 created "2023-06-01" @default.
- W4378901802 creator A5003642180 @default.
- W4378901802 creator A5034902543 @default.
- W4378901802 creator A5035173382 @default.
- W4378901802 creator A5038346531 @default.
- W4378901802 creator A5064368770 @default.
- W4378901802 creator A5077739374 @default.
- W4378901802 date "2023-08-01" @default.
- W4378901802 modified "2023-10-17" @default.
- W4378901802 title "Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab or Eculizumab: A Claims-Based Evaluation of Health Care Resource Utilization and Clinical Outcomes in the United States" @default.
- W4378901802 cites W1574141134 @default.
- W4378901802 cites W2006236530 @default.
- W4378901802 cites W2017235356 @default.
- W4378901802 cites W2098383030 @default.
- W4378901802 cites W2106675927 @default.
- W4378901802 cites W2118510193 @default.
- W4378901802 cites W2149943632 @default.
- W4378901802 cites W2158943356 @default.
- W4378901802 cites W2159884188 @default.
- W4378901802 cites W2264090971 @default.
- W4378901802 cites W2305176160 @default.
- W4378901802 cites W2405183840 @default.
- W4378901802 cites W2797057269 @default.
- W4378901802 cites W2966342106 @default.
- W4378901802 cites W2996668879 @default.
- W4378901802 cites W3009429865 @default.
- W4378901802 cites W3009860442 @default.
- W4378901802 cites W3011290754 @default.
- W4378901802 cites W3028115799 @default.
- W4378901802 cites W3085259011 @default.
- W4378901802 cites W3090724433 @default.
- W4378901802 cites W3091806808 @default.
- W4378901802 cites W3138369770 @default.
- W4378901802 cites W3138689598 @default.
- W4378901802 cites W3142113446 @default.
- W4378901802 cites W3167334836 @default.
- W4378901802 cites W3173737570 @default.
- W4378901802 cites W3184649349 @default.
- W4378901802 cites W3193704441 @default.
- W4378901802 cites W3202358903 @default.
- W4378901802 cites W3213860013 @default.
- W4378901802 cites W4206903450 @default.
- W4378901802 cites W4221038042 @default.
- W4378901802 cites W4226276968 @default.
- W4378901802 cites W4242833177 @default.
- W4378901802 cites W4300963246 @default.
- W4378901802 doi "https://doi.org/10.1016/j.xkme.2023.100683" @default.
- W4378901802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37415624" @default.
- W4378901802 hasPublicationYear "2023" @default.
- W4378901802 type Work @default.
- W4378901802 citedByCount "0" @default.
- W4378901802 crossrefType "journal-article" @default.
- W4378901802 hasAuthorship W4378901802A5003642180 @default.
- W4378901802 hasAuthorship W4378901802A5034902543 @default.
- W4378901802 hasAuthorship W4378901802A5035173382 @default.
- W4378901802 hasAuthorship W4378901802A5038346531 @default.
- W4378901802 hasAuthorship W4378901802A5064368770 @default.
- W4378901802 hasAuthorship W4378901802A5077739374 @default.
- W4378901802 hasBestOaLocation W43789018021 @default.
- W4378901802 hasConcept C111684460 @default.
- W4378901802 hasConcept C159654299 @default.
- W4378901802 hasConcept C160735492 @default.
- W4378901802 hasConcept C162324750 @default.
- W4378901802 hasConcept C177713679 @default.
- W4378901802 hasConcept C187212893 @default.
- W4378901802 hasConcept C203014093 @default.
- W4378901802 hasConcept C2777637130 @default.
- W4378901802 hasConcept C2777991916 @default.
- W4378901802 hasConcept C50522688 @default.
- W4378901802 hasConcept C71924100 @default.
- W4378901802 hasConceptScore W4378901802C111684460 @default.
- W4378901802 hasConceptScore W4378901802C159654299 @default.
- W4378901802 hasConceptScore W4378901802C160735492 @default.
- W4378901802 hasConceptScore W4378901802C162324750 @default.
- W4378901802 hasConceptScore W4378901802C177713679 @default.
- W4378901802 hasConceptScore W4378901802C187212893 @default.
- W4378901802 hasConceptScore W4378901802C203014093 @default.
- W4378901802 hasConceptScore W4378901802C2777637130 @default.
- W4378901802 hasConceptScore W4378901802C2777991916 @default.
- W4378901802 hasConceptScore W4378901802C50522688 @default.
- W4378901802 hasConceptScore W4378901802C71924100 @default.
- W4378901802 hasFunder F4320314126 @default.
- W4378901802 hasIssue "8" @default.
- W4378901802 hasLocation W43789018021 @default.
- W4378901802 hasLocation W43789018022 @default.
- W4378901802 hasLocation W43789018023 @default.
- W4378901802 hasOpenAccess W4378901802 @default.
- W4378901802 hasPrimaryLocation W43789018021 @default.
- W4378901802 hasRelatedWork W2077986770 @default.
- W4378901802 hasRelatedWork W2128719952 @default.
- W4378901802 hasRelatedWork W2135754582 @default.
- W4378901802 hasRelatedWork W2141534367 @default.
- W4378901802 hasRelatedWork W2765109318 @default.
- W4378901802 hasRelatedWork W2797427723 @default.
- W4378901802 hasRelatedWork W3031312213 @default.
- W4378901802 hasRelatedWork W3048772093 @default.
- W4378901802 hasRelatedWork W4226173199 @default.